InfuSystem Holdings, Inc. reported a financial performance for the fiscal year ending December 31, 2025, with total net revenues of $143.4 million, reflecting an increase of $8.6 million, or 6.4%, compared to $134.9 million in 2024. The growth was driven by both the Patient Services segment, which generated $86.5 million (up 7.7% from the previous year), and the Device Solutions segment, which saw revenues rise to $56.9 million (up 4.4%). The company also reported a net income of $6.6 million, a significant increase from $2.3 million in the prior year, resulting in a diluted earnings per share of $0.31, compared to $0.11 in 2024.
The company experienced notable changes in its operational metrics, including a gross profit of $80.3 million, which increased by 14.1% from $70.4 million in 2024. The gross margin improved to 56.0%, up from 52.2% in the previous year. The increase in gross profit was attributed to higher revenues and improved gross margins across both segments. The Patient Services segment's gross margin decreased slightly to 64.0%, while the Device Solutions segment saw a significant increase in gross margin to 43.8%, up 11.6% from the prior year.
Strategically, InfuSystem made significant advancements, including the acquisition of Apollo Medical Supply in May 2025, which enhanced its wound care services. The company also expanded its product offerings, adding Pneumatic Compression Devices to its portfolio and establishing partnerships to distribute innovative products aimed at improving patient outcomes. As of December 31, 2025, InfuSystem had contracts with nearly 840 third-party payer networks, a 1% increase from the previous year, indicating a stable growth in its payer relationships.
Operationally, InfuSystem maintained a workforce of 473 employees, with a focus on enhancing its service capabilities. The company reported a rental fleet of medical equipment valued at $109.1 million, up from $107.0 million in 2024. The company’s liquidity position improved, with cash and cash equivalents rising to $3.2 million from $0.5 million in the previous year, and available liquidity under its revolving credit facility increased to $55 million. Looking ahead, InfuSystem expressed optimism about its growth trajectory, driven by its strategic initiatives and the ongoing demand for its services in the healthcare sector.
About InfuSystem Holdings, Inc
InfuSystem Holdings, Inc. provides healthcare services and equipment solutions specializing in outpatient infusion therapy, primarily for oncology and pain management. Its core offerings include rental, sale, and servicing of infusion pumps, along with logistics, billing, and biomedical support. Serving hospitals, clinics, and healthcare providers across North America, the company leverages long-standing relationships, extensive equipment fleets, and technology-driven services to improve patient care and reduce costs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.